Trials / Active Not Recruiting
Active Not RecruitingNCT04736173
Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer
Official Title: A Phase 2 Study to Evaluate Zimberelimab (AB122) Combined With AB154 in Front-Line, PD-L1-High, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 169 (actual)
- Sponsor
- Arcus Biosciences, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase 2 study to evaluate zimberelimab (AB122) combined with domvanalimab (AB154) in front-line, PD-L1-high, locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC).
Conditions
- Non Small Cell Lung Cancer
- Nonsquamous Non Small Cell Lung Cancer
- Squamous Non Small Cell Lung Cancer
- Lung Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Domvanalimab | Domvanalimab is a humanized monoclonal antibody targeting human TIGIT |
| DRUG | Zimberelimab | Zimberelimab is a fully human anti-PD-1 monoclonal antibody |
| DRUG | Carboplatin | Participants receive carboplatin, pemetrexed, and paclitaxel at a target area under the curve. |
| DRUG | Paclitaxel | Participants receive carboplatin, pemetrexed, and paclitaxel at a target area under the curve. |
| DRUG | Pemetrexed | Participants receive carboplatin, pemetrexed, and paclitaxel at a target area under the curve. |
| DRUG | Pembrolizumab | Pembrolizumab is a humanized Immunoglobulin G4 monoclonal antibody targeting the PD-1 receptor |
Timeline
- Start date
- 2021-02-08
- Primary completion
- 2027-05-01
- Completion
- 2027-05-01
- First posted
- 2021-02-03
- Last updated
- 2026-03-30
Locations
56 sites across 10 countries: United States, Hong Kong, Malaysia, Philippines, South Africa, South Korea, Taiwan, Thailand, Turkey (Türkiye), Vietnam
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04736173. Inclusion in this directory is not an endorsement.